2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors
- 15 September 2003
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (18), 2993-2996
- https://doi.org/10.1016/s0960-894x(03)00632-2
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Synthesis and biological activity of olomoucine IIBioorganic & Medicinal Chemistry Letters, 2002
- In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)International Journal of Cancer, 2002
- Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the FutureCurrent Topics in Medicinal Chemistry, 2002
- Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 withO6-Substituted Guanine DerivativesJournal of Medicinal Chemistry, 2002
- A p34cdc2 survival checkpoint in cancerCancer Cell, 2002
- THE DESIGN AND SYNTHESIS OF PURINE INHIBITORS OF CDK2. IIINucleosides, Nucleotides and Nucleic Acids, 2001
- Crystal Structure of Human Cyclin-Dependent Kinase 2 in Complex with the Adenine-Derived Inhibitor H717Journal of Medicinal Chemistry, 2000
- Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase InhibitorsScience, 1998
- Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related CompoundsJournal of Medicinal Chemistry, 1997
- Inhibition of Cyclin‐Dependent Kinases by Purine AnaloguesEuropean Journal of Biochemistry, 1994